An experimental vaccine provided broad protection against all 20 known influenza A and B virus subtypes in initial tests in mice and ferrets, potentially opening a pathway to a universal flu shot that might help prevent future pandemics, according to a U.S. study published on Thursday.

RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.

The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.

The two companies will work to advance vaccines against COVID-19, influenza, pandemic preparedness and three other common respiratory infectious diseases.

Australia’s CSL Ltd. said on Wednesday it had struck a licensing deal with Arcturus Therapeutics Holdings Inc. that would help it gain access to the U.S. drug developer’s messenger RNA (mRNA) vaccine technology.

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the United States for children as young as five years of age. The FDA also approved the drug to prevent influenza in children aged five years and older following contact with an infected person.

In a busy 24 hours of launches, Flagship Pioneering announced Apriori Bio, which utilizes artificial intelligence to predict virus activity and variant formation, including in COVID-19. 

COVID-19 cases in the Americas increased 10.4 percent last week from the previous one, but countries must also pay attention to a rise in other respiratory viruses in the region, the Pan American Health Organization (PAHO) said on Wednesday.